Funding Disclosure

This educational activity is supported by an independent medical educational grant from Merck Sharp & Dohme Corp and Takeda.

Activity Description and Educational Objectives

In this activity, an expert in cytomegalovirus (CMV) management discusses the impact of CMV infection on patients receiving transplantation and how prophylaxis or preemptive therapy can improve patient outcomes.

Upon completion of this activity, participants should be better able to:

• Explain the impact of cytomegalovirus (CMV) reactivation for transplant recipients in terms of patient outcomes and healthcare utilisation
• Analyse unmet needs associated with historical strategies to prevent CMV disease in transplant recipients
• Evaluate how the efficacy and safety of novel therapies for CMV in transplant recipients may address current unmet needs and impact patient outcomes now and into the future

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, hepatologists, transplant surgeons, pharmacists and other clinicians involved in the management of CMV infection.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director

Genovefa Papanicolaou, MD
Professor, Department of Medicine
Weill Cornell Medical College, Cornell University
Director Clinical Trials, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
New York, New York, USA

Genovefa Papanicolaou, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for ADMA Biologics, Inc.; Cidara Therapeutics, Inc.; Merck Sharp & Dohme Corp.; and Partners Rx Management, LLC.
Grant/Research Support from Astellas Pharma Inc.; Chimerix, Inc.; Equinox Pharma Limited; Merck Sharp & Dohme Corp.; and Takeda Pharmaceutical Company Limited.
Advisory Board for ADMA Biologics, Inc.; Cidara Therapeutics, Inc.; Octapharma AG; Partners Rx Management, LLC; Pulmotect Inc.; and Shionogi & Co., Ltd.

PeerVoice Medical Director

Annette Wiggins has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and PeerVoice. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing designates this enduring material for a maximum of 0.5  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: 8 September 2020 - 7 September 2021
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.